Evidence map›Paper›PMID 31557691›Full record

ReviewCurrent opinion in immunology2019

Shared and unique immune alterations in pre-clinical autoimmunity.

Samantha Slight-Webb, Rebecka L Bourn, V Michael Holers, Judith A James

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Pathogenesis of autoimmune disease.Nature reviews. Nephrology · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Finding lupus in the ANA haystack.Lupus science & medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Samantha Slight-WebbArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Rebecka L BournArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
V Michael HolersMedicine and Rheumatology, University of Colorado School of Medicine, Aurora, CO 80045, United States.
Judith A JamesArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States; Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States. Electronic address: Judith-James@omrf.org.
Oklahoma Medical Research Foundation · USUniversity of Colorado Denver · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
Virginia Mason/UCHSC Autoimmune Prevention CenterU19AI050864 · NIAID · UNIVERSITY OF COLORADO DENVER · PI EISENBARTH, GEORGE S · 2001 to 2011
$29.2M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2009 to 2018
$6.2M
Prevention Center U01: Early Targets for Antigen-Specific Tolerance Induction in Preclinical Rheumatoid ArthritisU01AI101981 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2012 to 2021
$6.2M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
RA-Related Autoantibodies in Healthy FDR of RA PatientsR01AR051394 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI NORRIS, JILL M · 2005 to 2011
$3.0M
Mechanisms of Lupus Disease Transition and Hydroxychloroquine Immune ModulationR01AR072401 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2017 to 2020
$1.8M
Evolution of Autoimmunity in Rheumatoid ArthritisR21AI061479 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2004 to 2005
$385k
NIAID NIH HHS R21 AI061479NIAID NIH HHS U01 AI101981NIAID NIH HHS U19 AI050864NIAID NIH HHS U19 AI082714NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR073750NIAMS NIH HHS R01 AR051394NIAMS NIH HHS R01 AR072401NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Progression from health to a classified autoimmune disease is an evolving process that can happen rapidly in some diseases, but usually takes years to develop. Specific immune alterations predate pathogenic autoimmunity and can be used as disease biomarkers to identify high-risk individuals for prevention studies applied in the pre-clinical state. Here we discuss recent findings that illuminate specific immune pathways that are altered in the earliest phases of pre-clinical autoimmunity as well as those mediators more closely associated with later clinically apparent and classified disease onset.

Indexed as

AutoimmunityAnimalsAutoantibodiesAutoimmune DiseasesBiomarkersB-LymphocytesCytokinesDisease Models, AnimalDisease SusceptibilityHumansSelf ToleranceSeroconversionSignal TransductionAutoantibodiesBiomarkersCytokines

Identifiers

PMID31557691
PMCPMC6901719
OpenAlexW2975446496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.